Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
Add more filters










Publication year range
1.
Int J Radiat Oncol Biol Phys ; 112(5): 1269-1278, 2022 04 01.
Article in English | MEDLINE | ID: mdl-34963556

ABSTRACT

PURPOSE: Tumor-treating fields (TTFields) are an antimitotic treatment modality that interfere with glioblastoma (GBM) cell division and organelle assembly by delivering low-intensity, alternating electric fields to the tumor. A previous analysis from the pivotal EF-14 trial demonstrated a clear correlation between TTFields dose density at the tumor bed and survival in patients treated with TTFields. This study tests the hypothesis that the antimitotic effects of TTFields result in measurable changes in the location and patterns of progression of newly diagnosed GBM. METHODS AND MATERIALS: Magnetic resonance images of 428 newly diagnosed GBM patients who participated in the pivotal EF-14 trial were reviewed, and the rates at which distant progression occurred in the TTFields treatment and control arm were compared. Realistic head models of 252 TTFields-treated patients were created, and TTFields intensity distributions were calculated using a finite element method. The TTFields dose was calculated within regions of the tumor bed and normal brain, and its relationship with progression was determined. RESULTS: Distant progression was frequently observed in the TTFields-treated arm, and distant lesions in the TTFields-treated arm appeared at greater distances from the primary lesion than in the control arm. Distant progression correlated with improved clinical outcome in the TTFields patients, with no such correlation observed in the controls. Areas of normal brain that remained normal were exposed to higher TTFields doses compared with normal brain that subsequently exhibited neoplastic progression. Additionally, the average dose to areas of the enhancing tumor that returned to normal was significantly higher than in the areas of the normal brain that progressed to enhancing tumor. CONCLUSIONS: There was a direct correlation between TTFields dose distribution and tumor response, confirming the therapeutic activity of TTFields and the rationale for optimizing array placement to maximize the TTFields dose in areas at highest risk of progression, as well as array layout adaptation after progression.


Subject(s)
Antimitotic Agents , Brain Neoplasms , Electric Stimulation Therapy , Glioblastoma , Antimitotic Agents/therapeutic use , Brain/diagnostic imaging , Brain/pathology , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/radiotherapy , Electric Stimulation Therapy/methods , Glioblastoma/diagnostic imaging , Glioblastoma/radiotherapy , Humans , Magnetic Resonance Imaging
2.
Annu Int Conf IEEE Eng Med Biol Soc ; 2021: 4192-4195, 2021 11.
Article in English | MEDLINE | ID: mdl-34892148

ABSTRACT

In this work we investigated the relation between the power density in the tumor and the maximum temperature reached in the scalp during TTFields treatment for glioblastoma. We used a realistic head model to perform the simulations in COMSOL Multiphysics and we solved Pennes' equation to obtain the temperature distribution. Our results indicate that there might be a linear relation between these two quantities and that TTFields are safe from a thermal point of view.


Subject(s)
Brain Neoplasms , Electric Stimulation Therapy , Glioblastoma , Brain Neoplasms/therapy , Glioblastoma/therapy , Humans , Scalp , Temperature
3.
Front Oncol ; 11: 670809, 2021.
Article in English | MEDLINE | ID: mdl-34249709

ABSTRACT

BACKGROUND: Tumor Treating Fields (TTFields) therapy is a non-invasive, loco-regional, anti-mitotic treatment modality that targets rapidly dividing cancerous cells, utilizing low intensity, alternating electric fields at cancer-cell-type specific frequencies. TTFields therapy is approved for the treatment of newly diagnosed and recurrent glioblastoma (GBM) in the US, Europe, Israel, Japan, and China. The favorable safety profile of TTFields in patients with GBM is partially attributed to the low rate of mitotic events in normal, quiescent brain cells. However, specific safety evaluations are warranted at locations with known high rates of cellular proliferation, such as the torso, which is a primary site of several of the most aggressive malignant tumors. METHODS: The safety of delivering TTFields to the torso of healthy rats at 150 or 200 kHz, which were previously identified as optimal frequencies for treating multiple torso cancers, was investigated. Throughout 2 weeks of TTFields application, animals underwent daily clinical examinations, and at treatment cessation blood samples and internal organs were examined. Computer simulations were performed to verify that the targeted internal organs of the torso were receiving TTFields at therapeutic intensities (≥ 1 V/cm root mean square, RMS). RESULTS: No treatment-related mortality was observed. Furthermore, no significant differences were observed between the TTFields-treated and control animals for all examined safety parameters: activity level, food and water intake, stools, motor neurological status, respiration, weight, complete blood count, blood biochemistry, and pathological findings of internal organs. TTFields intensities of 1 to 2.5 V/cm RMS were confirmed for internal organs within the target region. CONCLUSIONS: This research demonstrates the safety of therapeutic level TTFields at frequencies of 150 and 200 kHz when applied as monotherapy to the torso of healthy rats.

4.
Cancers (Basel) ; 13(9)2021 May 10.
Article in English | MEDLINE | ID: mdl-34068775

ABSTRACT

The biological impact of exogenous, alternating electric fields (AEFs) and direct-current electric fields has a long history of study, ranging from effects on embryonic development to influences on wound healing. In this article, we focus on the application of electric fields for the treatment of cancers. In particular, we outline the clinical impact of tumor treating fields (TTFields), a form of AEFs, on the treatment of cancers such as glioblastoma and mesothelioma. We provide an overview of the standard mechanism of action of TTFields, namely, the capability for AEFs (e.g., TTFields) to disrupt the formation and segregation of the mitotic spindle in actively dividing cells. Though this standard mechanism explains a large part of TTFields' action, it is by no means complete. The standard theory does not account for exogenously applied AEFs' influence directly upon DNA nor upon their capacity to alter the functionality and permeability of cancer cell membranes. This review summarizes the current literature to provide a more comprehensive understanding of AEFs' actions on cell membranes. It gives an overview of three mechanistic models that may explain the more recent observations into AEFs' effects: the voltage-gated ion channel, bioelectrorheological, and electroporation models. Inconsistencies were noted in both effective frequency range and field strength between TTFields versus all three proposed models. We addressed these discrepancies through theoretical investigations into the inhomogeneities of electric fields on cellular membranes as a function of disease state, external microenvironment, and tissue or cellular organization. Lastly, future experimental strategies to validate these findings are outlined. Clinical benefits are inevitably forthcoming.

5.
Rep Pract Oncol Radiother ; 26(6): 1045-1050, 2021.
Article in English | MEDLINE | ID: mdl-34992879

ABSTRACT

BACKGROUND AND PURPOSE: Tumor treating fields (TTFields) are a non-invasive, efficacious treatment modality currently approved for supratentorial glioblastomas. Despite their ability to improve overall survival in supratentorial tumors, the current placement of arrays is limited to the supratentorial head, precluding its use in infratentorial tumors. Infratentorial malignancies are in need of new therapy modalities given their poor prognoses in both children and adults. The aim of this research is to determine whether rearrangement of TTFields may allow for management of infratentorial tumors. MATERIALS AND METHODS: Delivery of TTFields using Novocure's prototype Optune™ device human male head model was simulated based on brain MRIs from patients with brainstem gliomas to develop a novel array layout designed to extend adequate infratentorial coverage. RESULTS: Array placement on the vertex, bilateral posterolateral occiput, and superior-posterior neck achieved intensities above 1.1 V/cm (average 1.7 V/cm; maximum 2.3 V/cm) in the vertical field direction and above 1 V/cm (average 2 V/cm; maximum 2.8 V/cm) in the horizontal field direction of the infratentorium. The calculated field intensity within the simulated tumors were in the therapeutic range and demonstrated the effective delivery of TTFields to the infratentorial brain. CONCLUSIONS: Our findings suggest that rearrangement of the TTFields standard array with placement of electrodes on the vertex, bilateral posterolateral occiput, and superior-posterior neck allows for adequate electric field distribution in the infratentorium that is within the therapeutic range.

6.
Cancers (Basel) ; 12(10)2020 Oct 17.
Article in English | MEDLINE | ID: mdl-33080774

ABSTRACT

Tumor Treating Fields (TTFields) are noninvasive, alternating electric fields within the intermediate frequency range (100-300 kHz) that are utilized as an antimitotic cancer treatment. TTFields are loco-regionally delivered to the tumor region through 2 pairs of transducer arrays placed on the skin. This novel treatment modality has been FDA-approved for use in patients with glioblastoma and malignant pleural mesothelioma based on clinical trial data demonstrating efficacy and safety; and is currently under investigation in other types of solid tumors. TTFields were shown to induce an anti-mitotic effect by exerting bi-directional forces on highly polar intracellular elements, such as tubulin and septin molecules, eliciting abnormal microtubule polymerization during spindle formation as well as aberrant cleavage furrow formation. Previous studies have demonstrated that TTFields inhibit metastatic properties in cancer cells. However, the consequences of TTFields application on cytoskeleton dynamics remain undetermined. In this study, methods utilized in combination to study the effects of TTFields on cancer cell motility through regulation of microtubule and actin dynamics included confocal microscopy, computational tools, and biochemical analyses. Mechanisms by which TTFields treatment disrupted cellular polarity were (1) interference with microtubule assembly and directionality; (2) altered regulation of Guanine nucleotide exchange factor-H1 (GEF-H1), Ras homolog family member A (RhoA), and Rho-associated coiled-coil kinase (ROCK) activity; and (3) induced formation of radial protrusions of peripheral actin filaments and focal adhesions. Overall, these data identified discrete effects of TTFields that disrupt processes crucial for cancer cell motility.

7.
Phys Med Biol ; 64(18): 185014, 2019 09 19.
Article in English | MEDLINE | ID: mdl-31323651

ABSTRACT

The study of the dielectric properties of tissues plays a key role in understanding the interaction between electromagnetic energy and the human body, for safety assessments of human exposure to electromagnetic fields, as well as for numerous biomedical applications such as tumor treating fields (TTFields). TTFields are low-intensity alternating electric fields in the 100-500 kHz frequency range, which have an antimitotic effect on cancerous cells. TTFields are delivered to the body through pairs of transducer arrays placed on a patient's skin in close proximity to the tumor. Therefore, it is essential to understand how the skin's dielectric properties affect TTFields delivery in clinical settings. In this paper, we present a study combining in vivo measurements with numerical simulations that elucidate how different layers of the skin influence TTFields distribution in the body. The dielectric properties of the skin were measured on volunteers using a setup that ensured skin conditions resembled those when TTFields are delivered to patients. The measured properties were incorporated into a realistic human computational phantom and delivery of TTFields to the phantom's abdomen was simulated. The total impedance of the simulated model was within the mid-range of impedance values measured in patients with pancreatic cancer treated with TTFields. A computational study investigating model sensitivity to the dielectric properties of the skin and subcutaneous adipose tissue (SAT) showed that when skin conductivity increased above a threshold value, the total impedance of the model was largely insensitive to changes in the conductivity of these tissues. Furthermore, for a given current, the field intensity within the internal organs was mostly unaffected by skin properties but was highly sensitive to the conductivity of the organ itself. This study provides a new insight into the role of skin in determining the distribution of TTFields within the body.


Subject(s)
Electric Stimulation Therapy , Neoplasms/therapy , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/therapy , Skin/pathology , Transducers , Computer Simulation , Electric Conductivity , Electric Impedance , Electromagnetic Fields , Female , Humans , Male , Models, Theoretical , Phantoms, Imaging , Torso
8.
Int J Radiat Oncol Biol Phys ; 104(5): 1106-1113, 2019 08 01.
Article in English | MEDLINE | ID: mdl-31026557

ABSTRACT

INTRODUCTION: Tumor Treating Fields (TTFields) are approved for glioblastoma based on improved overall survival (OS) and progression-free survival (PFS) in the phase 3 EF-14 trial of newly diagnosed glioblastoma. To test the hypothesis that increasing TTFields dose at the tumor site improves patient outcomes, we performed a simulation-based study investigating the association between TTFields dose and survival (OS and PFS) in patients treated with TTFields in EF-14. METHODS AND MATERIALS: EF-14 patient cases (N = 340) were included. Realistic head models were derived from T1-contrast images captured at baseline. The transducer array layout on each patient was obtained from EF-14 records; average compliance (fraction of time patient was on active treatment) and average electrical current delivered to the patient were derived from log files of the TTFields devices used by patients. TTFields intensity distributions and power densities were calculated using the finite element method. Local minimum dose density (LMiDD) was defined as the product of TTFields intensity, tissue-specific conductivities, and patient compliance. The average LMiDD within a tumor bed comprising the gross tumor volume and the 3-mm-wide peritumoral boundary zone was calculated. RESULTS: The median OS and PFS were significantly longer when the average LMiDD in the tumor bed was ≥0.77 mW/cm3: OS was 25.2 versus 20.4 months (P = .003, hazard ratio [HR] = 0.611) and PFS was 8.5 versus 6.7 months (P = .02, HR = 0.699). The median OS and PFS were longer when the average TTFields intensity was >1.06 V/cm: OS was 24.3 versus 21.6 months (P = .03, HR = 0.705) and PFS was 8.1 versus 7.9 months (P = .03, HR = 0.721). CONCLUSIONS: In this study we present the first reported analysis demonstrating patient-level dose responses to TTFields. We provide a rigorous definition for TTFields dose and set a conceptual framework for future work on TTFields dosimetry and treatment planning.


Subject(s)
Brain Neoplasms/mortality , Brain Neoplasms/radiotherapy , Glioblastoma/mortality , Glioblastoma/radiotherapy , Adult , Aged , Aged, 80 and over , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/pathology , Electrophysiological Phenomena , Female , Glioblastoma/diagnostic imaging , Glioblastoma/pathology , Humans , Kaplan-Meier Estimate , Magnetic Resonance Imaging , Male , Middle Aged , Progression-Free Survival , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted , Transducers , Young Adult
9.
Annu Int Conf IEEE Eng Med Biol Soc ; 2019: 6995-6997, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31947448

ABSTRACT

Skull-remodeling surgery has been proposed to enhance the dose of tumor treating fields in glioblastoma treatment. This abstract describes the finite element methods used to plan the surgery and evaluate the treatment efficacy.


Subject(s)
Brain Neoplasms , Brain Neoplasms/surgery , Finite Element Analysis , Glioblastoma , Humans , Skull , Treatment Outcome
10.
IEEE Rev Biomed Eng ; 11: 195-207, 2018.
Article in English | MEDLINE | ID: mdl-29993870

ABSTRACT

Tumor-treating fields (TTFields) are a cancer treatment modality that uses alternating electric fields of intermediate frequency (∼100-500 kHz) and low intensity (1-3 V/cm) to disrupt cell division. TTFields are delivered by transducer arrays placed on the skin close to the tumor and act regionally and noninvasively to inhibit tumor growth. TTFields therapy is U.S. Food and Drug Administration approved for the treatment of glioblastoma multiforme, the most common and aggressive primary human brain cancer. Clinical trials testing the safety and efficacy of TTFields for other solid tumor types are underway. The objective of this paper is to review computational approaches used to characterize TTFields. The review covers studies of the macroscopic spatial distribution of TTFields generated in the human head, and of the microscopic field distribution in tumor cells. In addition, preclinical and clinical findings related to TTFields and principles of its operation are summarized. Particular emphasis is put on outlining the potential clinical value inferred from computational modeling.


Subject(s)
Brain Neoplasms/therapy , Computer Simulation , Electric Stimulation Therapy , Glioblastoma/therapy , Models, Biological , Electromagnetic Fields , Head/physiology , Humans , United States
11.
Radiat Oncol ; 12(1): 206, 2017 Dec 29.
Article in English | MEDLINE | ID: mdl-29284495

ABSTRACT

BACKGROUND: Tumor Treating Fields (TTFields) are an anti-neoplastic treatment modality delivered via application of alternating electric fields using insulated transducer arrays placed directly on the skin in the region surrounding the tumor. A Phase 3 clinical trial has demonstrated the effectiveness of continuous TTFields application in patients with glioblastoma during maintenance treatment with Temozolomide. The goal of this study was to evaluate the efficacy of combining TTFields with radiation treatment (RT) in glioma cells. We also examined the effect of TTFields transducer arrays on RT distribution in a phantom model and the impact on rat skin toxicity. METHODS: The efficacy of TTFields application after induction of DNA damage by RT or bleomycin was tested in U-118 MG and LN-18 glioma cells. The alkaline comet assay was used to measure repair of DNA lesions. Repair of DNA double strand breaks (DSBs) were assessed by analyzing γH2AX or Rad51 foci. DNA damage and repair signaled by the activation pattern of phospho-ATM (pS1981) and phospho-DNA-PKcs (pS2056) was evaluated by immunoblotting. The absorption of the RT energy by transducer arrays was measured by applying RT through arrays placed on a solid-state phantom. Skin toxicities were tested in rats irradiated daily through the arrays with 2Gy (total dose of 20Gy). RESULTS: TTFields synergistically enhanced the efficacy of RT in glioma cells. Application of TTFields to irradiated cells impaired repair of irradiation- or chemically-induced DNA damage, possibly by blocking homologous recombination repair. Transducer arrays presence caused a minor reduction in RT intensity at 20 mm and 60 mm below the arrays, but led to a significant increase in RT dosage at the phantom surface jeopardizing the "skin sparing effect". Nevertheless, transducer arrays placed on the rat skin during RT did not lead to additional skin reactions. CONCLUSIONS: Administration of TTFields after RT increases glioma cells treatment efficacy possibly by inhibition of DNA damage repair. These preclinical results support the application of TTFields therapy immediately after RT as a viable regimen to enhance RT outcome. Phantom measurements and animal models imply that it may be possible to leave the transducer arrays in place during RT without increasing skin toxicities.


Subject(s)
DNA Breaks, Double-Stranded/radiation effects , DNA Repair/radiation effects , Electric Stimulation Therapy , Glioma/radiotherapy , Phantoms, Imaging , Skin Diseases/prevention & control , Animals , Glioma/genetics , Glioma/pathology , Humans , Rats , Rats, Sprague-Dawley , Tumor Cells, Cultured
12.
IEEE Pulse ; 8(4): 46-49, 2017.
Article in English | MEDLINE | ID: mdl-28715315

ABSTRACT

Cancer represents a compilation of diseases characterized by rapidly dividing, invasive cells. Worldwide data indicate that over 14 million new cancers were diagnosed in 2012, with a projected increase of more than 19 million diagnosed cases by 2025 [1]. Survival rates for some cancers have increased dramatically, but there are still cancer types for which the prognosis is poor and few treatments exist. Thus, there is a growing need for new therapies targeting these difficult-to-treat cancers.


Subject(s)
Neoplasms , User-Computer Interface , Humans , Neoplasms/diagnosis , Neoplasms/therapy
13.
Int J Cancer ; 139(12): 2850-2858, 2016 Dec 15.
Article in English | MEDLINE | ID: mdl-27561100

ABSTRACT

Long-term survival rates for advanced ovarian cancer patients have not changed appreciably over the past four decades; therefore, development of new, effective treatment modalities remains a high priority. Tumor Treating Fields (TTFields), a clinically active anticancer modality utilize low-intensity, intermediate frequency, alternating electric fields. The goal of this study was to evaluate the efficacy of combining TTFields with paclitaxel against ovarian cancer cells in vitro and in vivo. In vitro application of TTFields on human ovarian cancer cell lines led to a significant reduction in cell counts as compared to untreated cells. The effect was found to be frequency and intensity dependent. Further reduction in the number of viable cells was achieved when TTFields treatment was combined with paclitaxel. The in vivo effect of the combined treatment was tested in mice orthotopically implanted with MOSE-LTICv cells. In this model, combined treatment led to a significant reduction in tumor luminescence and in tumor weight as compared to untreated mice. The feasibility of effective local delivery of TTFields to the human abdomen was examined using finite element mesh simulations performed using the Sim4life software. These simulations demonstrated that electric fields intensities inside and in the vicinity of the ovaries of a realistic human computational phantom are about 1 and 2 V/cm pk-pk, respectively, which is within the range of intensities required for TTFields effect. These results suggest that prospective clinical investigation of the combination of TTFields and paclitaxel is warranted.


Subject(s)
Antineoplastic Agents/pharmacology , Ovarian Neoplasms/pathology , Paclitaxel/pharmacology , Animals , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/radiation effects , Combined Modality Therapy , Disease Models, Animal , Female , Humans , Mice , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/therapy , Treatment Outcome , Xenograft Model Antitumor Assays
14.
Annu Int Conf IEEE Eng Med Biol Soc ; 2016: 2357-2360, 2016 Aug.
Article in English | MEDLINE | ID: mdl-28268799

ABSTRACT

Tumor Treating Fields (TTFields) are low intensity alternating electric fields in the 100-500 KHz frequency range that are known to have an anti-mitotic effect on cancerous cells. In the USA, TTFields are approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM) in both the newly diagnosed and recurrent settings. Optimizing treatment with TTFields requires a deep understanding of how TTFields distribute within the brain. To address this issue, simulations using realistic head models have been performed. However, the preparation of such models is time-consuming and requires a high level of expertise, limiting the usefulness of these models for systematic studies in which the testing of multiple cases is required. Here we present a platform for rapidly simulating TTFields distributions in multiple scenarios. This platform enables high throughput computational simulations to be performed, allowing comparison of field distributions within the head in multiple clinically relevant scenarios. The simulation setup is simple and intuitive, allowing non-expert users to run simulations and evaluate results, thereby providing a valuable tool for studying how to optimize TTFields delivery in the clinic.


Subject(s)
Brain Neoplasms/therapy , Electric Stimulation Therapy , Glioblastoma/therapy , Brain , Computer Simulation , Electricity , Head , Humans , Models, Theoretical
15.
Annu Int Conf IEEE Eng Med Biol Soc ; 2016: 5664-5667, 2016 Aug.
Article in English | MEDLINE | ID: mdl-28269540

ABSTRACT

Tumor Treating Fields (TTFields) are alternating electric fields in the intermediate frequency range (100-300 kHz) of low-intensity (1-3 V/cm). TTFields are an anti-mitotic treatment against solid tumors, which are approved for Glioblastoma Multiforme (GBM) patients. These electric fields are induced non-invasively by transducer arrays placed directly on the patient's scalp. Cell culture experiments showed that treatment efficacy is dependent on the induced field intensity. In clinical practice, a software called NovoTalTM uses head measurements to estimate the optimal array placement to maximize the electric field delivery to the tumor. Computational studies predict an increase in the tumor's electric field strength when adapting transducer arrays to its location. Ideally, a personalized head model could be created for each patient, to calculate the electric field distribution for the specific situation. Thus, the optimal transducer layout could be inferred from field calculation rather than distance measurements. Nonetheless, creating realistic head models of patients is time-consuming and often needs user interaction, because automated image segmentation is prone to failure. This study presents a first approach to creating simplified head models consisting of convex hulls of the tissue layers. The model is able to account for anisotropic conductivity in the cortical tissues by using a tensor representation estimated from Diffusion Tensor Imaging. The induced electric field distribution is compared in the simplified and realistic head models. The average field intensities in the brain and tumor are generally slightly higher in the realistic head model, with a maximal ratio of 114% for a simplified model with reasonable layer thicknesses. Thus, the present pipeline is a fast and efficient means towards personalized head models with less complexity involved in characterizing tissue interfaces, while enabling accurate predictions of electric field distribution.


Subject(s)
Brain Neoplasms/diagnostic imaging , Diffusion Tensor Imaging , Glioblastoma/diagnostic imaging , Brain/diagnostic imaging , Brain Neoplasms/pathology , Brain Neoplasms/therapy , Electric Conductivity , Female , Glioblastoma/pathology , Glioblastoma/therapy , Humans , Models, Biological , Young Adult
16.
Annu Int Conf IEEE Eng Med Biol Soc ; 2016: 6461-6464, 2016 Aug.
Article in English | MEDLINE | ID: mdl-28269726

ABSTRACT

This paper reviews the state-of-the-art in simulation-based studies of Tumor Treating Fields (TTFields) and highlights major aspects of TTFields in which simulation-based studies could affect clinical outcomes. A major challenge is how to simulate multiple scenarios rapidly for TTFields delivery. Overcoming this challenge will enable a better understanding of how TTFields distribution is correlated with disease progression, leading to better transducer array designs and field optimization procedures, ultimately improving patient outcomes.


Subject(s)
Computer Simulation , Electric Stimulation Therapy/instrumentation , Electric Stimulation Therapy/methods , Phantoms, Imaging , Animals , Cell Line, Tumor , Head , Humans , Neoplasms/therapy , Transducers
17.
Sci Rep ; 5: 18046, 2015 Dec 11.
Article in English | MEDLINE | ID: mdl-26658786

ABSTRACT

Tumor Treating Fields (TTFields) are low intensity, intermediate frequency, alternating electric fields. TTFields are a unique anti-mitotic treatment modality delivered in a continuous, noninvasive manner to the region of a tumor. It was previously postulated that by exerting directional forces on highly polar intracellular elements during mitosis, TTFields could disrupt the normal assembly of spindle microtubules. However there is limited evidence directly linking TTFields to an effect on microtubules. Here we report that TTFields decrease the ratio between polymerized and total tubulin, and prevent proper mitotic spindle assembly. The aberrant mitotic events induced by TTFields lead to abnormal chromosome segregation, cellular multinucleation, and caspase dependent apoptosis of daughter cells. The effect of TTFields on cell viability and clonogenic survival substantially depends upon the cell division rate. We show that by extending the duration of exposure to TTFields, slowly dividing cells can be affected to a similar extent as rapidly dividing cells.


Subject(s)
Chromosome Segregation/physiology , Mitosis/physiology , Neoplasms/pathology , Spindle Apparatus/pathology , Animals , Apoptosis/physiology , Cell Line, Tumor , Cell Survival/physiology , Electricity , Humans , MCF-7 Cells , Microtubules/metabolism , Microtubules/pathology , Neoplasms/metabolism , Rats , Rats, Inbred F344 , Tubulin/metabolism
18.
Article in English | MEDLINE | ID: mdl-26737877

ABSTRACT

Effects of electric fields on biological cells have been extensively studied but primarily in the low and high frequency regimes. Low frequency AC fields have been investigated for applications to nerve and muscle stimulation or to examine possible environmental effects of 60 Hz excitation. High frequency fields have been studied to understand tissue heating and tumor ablation. Biological effects at intermediate frequencies (in the 100-500 kHz regime) have only recently been discovered and are now being used clinically to disrupt cell division, primarily for the treatment of recurrent glioblastoma multiforme. In this study, we develop a computational framework to investigate the mechanisms of action of these Tumor Treating Fields (TTFields) and to understand in vitro findings observed in cell culture. Using Finite Element Method models of isolated cells we show that the intermediate frequency range is unique because it constitutes a transition region in which the intracellular electric field, shielded at low frequencies, increases significantly. We also show that the threshold at which this increase occurs depends on the dielectric properties of the cell membrane. Furthermore, our models of different stages of the cell cycle and of the morphological changes associated with cytokinesis show that peak dielectrophoretic forces develop within dividing cells exposed to TTFields. These findings are in agreement with in vitro observations, and enhance our understanding of how TTFields disrupt cellular function.


Subject(s)
Electric Stimulation Therapy/methods , Metaphase , Models, Theoretical , Neoplasms/pathology , Neoplasms/therapy , Telophase , Cell Line, Tumor , Electricity , Humans , Spindle Apparatus/metabolism
19.
Immunol Cell Biol ; 91(1): 70-81, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23032369

ABSTRACT

We describe a new approach for interactive analysis of time-lapse microscopy, and apply this approach to elucidating whether polarity regulation is conserved between epithelial cells and lymphocytes. A key advantage of our analysis platform, 'TACTICS', is the capacity to visualize individual data points in the context of large data sets, similar to standard approaches in flow cytometry. Scatter plots representing microscopic parameters or their derivations such as polarity ratios are linked to the original data such that clicking on each dot enables a link to images and movies of the corresponding cell. Similar to flow cytometric analysis, subsets of the data can be gated and reanalyzed to explore the relationships between different parameters. TACTICS was used to dissect the regulation of polarization of the cell fate determinant, Numb, in migrating lymphocytes. We show here that residues of Numb that are phosphorylated by atypical protein kinase C (aPKC) to mediate apicobasal polarity in epithelial cells are not required for polarization of Numb in T cells, indicating that the role of aPKC is not conserved between lymphocytes and epithelia.


Subject(s)
Image Processing, Computer-Assisted/methods , Lymphocytes/cytology , Lymphocytes/immunology , Signal Transduction/immunology , Animals , Cell Polarity/immunology , Epithelial Cells/cytology , Epithelial Cells/immunology , Image Processing, Computer-Assisted/instrumentation , Membrane Proteins/immunology , Mice , Microscopy, Fluorescence/instrumentation , Microscopy, Fluorescence/methods , Nerve Tissue Proteins/immunology , Organ Specificity/immunology , Phosphorylation/immunology , Protein Kinase C/immunology
20.
J Immunol ; 185(1): 367-75, 2010 Jul 01.
Article in English | MEDLINE | ID: mdl-20530266

ABSTRACT

Asymmetric cell division is a potential means by which cell fate choices during an immune response are orchestrated. Defining the molecular mechanisms that underlie asymmetric division of T cells is paramount for determining the role of this process in the generation of effector and memory T cell subsets. In other cell types, asymmetric cell division is regulated by conserved polarity protein complexes that control the localization of cell fate determinants and spindle orientation during division. We have developed a tractable, in vitro model of naive CD8(+) T cells undergoing initial division while attached to dendritic cells during Ag presentation to investigate whether similar mechanisms might regulate asymmetric division of T cells. Using this system, we show that direct interactions with APCs provide the cue for polarization of T cells. Interestingly, the immunological synapse disseminates before division even though the T cells retain contact with the APC. The cue from the APC is translated into polarization of cell fate determinants via the polarity network of the Par3 and Scribble complexes, and orientation of the mitotic spindle during division is orchestrated by the partner of inscuteable/G protein complex. These findings suggest that T cells have selectively adapted a number of evolutionarily conserved mechanisms to generate diversity through asymmetric cell division.


Subject(s)
Antigen Presentation/immunology , Cell Division/immunology , Conserved Sequence/immunology , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/immunology , Animals , Antigen-Presenting Cells/cytology , Antigen-Presenting Cells/immunology , CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cell Adhesion/immunology , Cell Polarity/immunology , Cells, Cultured , Mice , Mice, Inbred C57BL , Mice, Transgenic , T-Lymphocyte Subsets/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...